Aktienanalyse zu Celldex Therapeutics Inc (CLDX)CLDXCelldex Therapeutics Inc

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Celldex Therapeutics Inc is a good buy right now, trading at $29.89 with a strong upside potential. Analysts have set a price target of $64, indicating a potential upside of 114% from the current price. Additionally, the company has reported a gross margin of 100%, showcasing its strong profitability potential despite current losses. The main risk is its negative earnings per share (EPS) of -0.94, which reflects ongoing financial challenges.

7 analysts cover CLDX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 55.00.